Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Roche burnishes breast cancer portfolio with FDA nod for Itovebi
To be marketed under the brand name Itovebi, inavolisib is a threat to Novartis’ fellow PI3K inhibitor Piqray and AstraZeneca’s ATK inhibitor Truqap.
Angus Liu
Oct 10, 2024 5:30pm
B. Braun offers update on Florida manufacturing after Milton
Oct 10, 2024 2:54pm
Sponsored
AstraZeneca's vision for the future of respiratory care
Oct 7, 2024 8:00am
Warren challenges Novo Holdings' proposed Catalent buyout
Oct 10, 2024 2:16pm
Sponsored
Embracing AI and Human Connection
Oct 7, 2024 8:00am
Regulatory tracker: Alnylam uses PRV for Amvuttra app in ATTR-CM
Oct 10, 2024 11:20am
